dostarlimab + carboplatin + paclitaxel

This is a **combination regimen** of three drugs—dostarlimab, carboplatin, and paclitaxel—used primarily for the treatment of certain cancers, most notably **primary advanced or recurrent endometrial cancer**. - **Dostarlimab** is a humanized monoclonal antibody (IgG4) and an **anti-PD-1 immune checkpoint inhibitor**, enhancing T-cell mediated anti-tumor response by blocking the inhibition of cytotoxic T lymphocytes[2][3][7]. - **Carboplatin** is a platinum-based chemotherapy that forms DNA crosslinks leading to apoptosis in rapidly dividing cancer cells. - **Paclitaxel** is an antineoplastic agent which stabilizes microtubules and inhibits their depolymerization, leading to cell cycle arrest and apoptosis. The combination was approved by the FDA in 2024 for primary advanced or recurrent endometrial cancer and has shown meaningful overall survival benefits in clinical trials for this indication[3][7]. The therapy is also under investigation for other cancers, including triple-negative breast cancer[1]. Treatment regimens involve intravenous administration of all agents, with dostarlimab typically given before chemotherapy, followed by monotherapy[5][7]. Main toxicity includes hematologic, hepatic, and immune-related adverse events.

Brand names

Jemperli (for dostarlimab)Paraplatin (for carboplatin)Taxol (for paclitaxel)

Other names

dostarlimab-gxly + carboplatin + paclitaxel